Trial Profile
An observational real world study describing characteristics of patients prescribed Evolocumab in Europe.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2020
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Cardiovascular disorders; Hypercholesterolaemia
- Focus Therapeutic Use
- 01 Sep 2020 Results (n=779 of analysis predicting baseline CV risk and assessing potential risk reduction among a large European cohort of evolocumab users using interim data presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 19 Sep 2018 New trial record
- 29 Aug 2018 Interim results (n=476) presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology